Drug Profile
LY 3325656
Alternative Names: LY-3325656Latest Information Update: 28 Jun 2020
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class Antihyperglycaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 28 Jun 2020 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus(Combination therapy, In the elderly, In adults) in Singapore (PO)
- 28 Jun 2020 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus(In the elderly, Monotherapy, In adults) in Singapore (PO)
- 11 Jun 2019 Safety, efficacy and pharmacokinetic data from a phase I trial in Diabetes mellitus type 2 presented at the 79th Annual Scientific Sessions of the American Diabetes Association (ADA-2019)